MD Healthcare announced on the 18^th of November that it was selected as a technology innovation task in the second half of the BIG3 field of SME (Small Medium Enterprise) innovative growth support project managed by the Ministry of SMEs and Startups.

Among the three new industrial fields, the development technology is 'CMC and non-clinical research of MDH-101, a candidate for treating respiratory inflammatory diseases.' Through this project, development of a therapeutic for respiratory diseases such as viral pneumonia will begin in earnest.

The project period is from January 2021 to December 2022 and financial support will be approximately $540,000 (600 million KRW).

A new microbial drug using microbe-derived extracellular vesicles is a first-in-class drug worldwide and is the first candidate material of its kind developed by Korea in the world.

Through this project, the MD Healthcare research team will complete a pre-clinical test of the substance for treating respiratory diseases such as pneumonia caused by respiratory viruses like coronavirus using extracellular vesicles derived from microorganisms to prepare for and promote clinical trial entry.

Link: http://www.medigatenews.com/news/2527057350